A study noted an average weight loss of 17.6% with Allurion’s device in patients who had no or less than 5% weight loss with ...

US-based LumiThera has submitted a de novo request to reclassify the Valeda light delivery system as a Class II device, following the feedback from the FDA. Under the request process, the system ...

these supposed 'junk' patents covering the device and formulation of the drug are important to marketing Ozempic for weight loss, hence the fear that the FTC could disrupt Novo's business.

Novo is also exploring CagriSema’s efficacy as a treatment for type 2 diabetes. The key to the new combination ... a panel on ...

Last month Novo reached an agreement with digital device firm Medtronic to allow dosing ... and as a daily pill, in type 2 diabetes to help manage blood sugar levels. Camilla Sylvest, Novo Nordisk ...

Optune Lua is a portable device that produces alternating electric ... a PD-1/PD-L1 inhibitor or docetaxel had a median OS of 13.2 months compared to a median OS of 9.9 months in the PD-1/PD ...

Apple AI launches, Anthropic's AI can control your device and a bank introduces new tools for solopreneurs and small businesses.

The company, headquartered in the key swing state of Pennsylvania, has announced the creation of 330 jobs in a significant ...

With the presidential election season behind us, a major source of uncertainty has been lifted, creating an ideal opportunity for investors to ...